Drug intelligence / Profile preview

TX-944

Development stage: Preclinical
Lead developer: Nimbus Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

**TX-944** is a small molecule inhibitor of Cbl-b (Casitas B-lineage lymphoma b), an E3 ubiquitin ligase that negatively regulates T-cell activation. By inhibiting Cbl-b, TX-944 enhances T-cell mediated anti-tumor immunity, positioning it as a potential immunotherapy for cancer. It was initially developed by Nimbus Therapeutics LLC and remains in early preclinical development with no reported clinical trials or further advancement as of available data.[10]

Targets

CBLB (CBL-B)

Beyond the preview

Go deeper on TX-944.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TX-944.

Explore the full profile